Loading
FORT MYERS — NeoGenomics reported revenues and profits grew as it benefited from an acquisition it made last year.
NeoGenomics reported net income of $1.05 million on revenues of $25 million in the fourth quarter ending Dec. 31. That compares with net income of $857,000 on revenues of $18.3 million in the fourth quarter of 2013.
NeoGenomics acquired California-based PathLogic in July, a provider of specialized anatomic pathology services, for $6 million. The company says the acquisition accounted for 13% of the revenue growth in the fourth quarter.
“As we enter 2015, we believe we are exceptionally well positioned to commercialize the many scientific breakthroughs occurring in molecular testing,” says Douglas VanOort, the company' chairman and CEO, in a statement.
Headquartered with a lab in Fort Myers, NeoGenomics also has labs in Tampa, Nashville and Irvine, Cal. NeoGenomics provides cancer-testing services for pathologists, oncologists, other clinicians and hospitals throughout the United States.
Your free article limit has been reached this month.
Subscribe now for unlimited digital access to our award-winning business news.
Join thousands of executives who rely on us for insights spanning Tampa Bay to Naples.
